Vanda Pharmaceuticals | VNDA - Market Capitalization


Vanda Pharmaceuticals reported $337.7M in Market Capitalization this June of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 3.8B 724M Mar/2026
Agios Pharmaceuticals USD 2.01B 423M Mar/2026
Akebia Therapeutics USD 427M 297M Dec/2025
Alnylam Pharmaceuticals USD 44.15B 8.39B Mar/2026
Anika Therapeutics USD 139M 3M Dec/2025
Arrowhead Research USD 8.78B 236M Mar/2026
AstraZeneca USD 301.25B 13.1B Mar/2026
Bristol-Myers Squibb USD 123.83B 14.02B Mar/2026
Eli Lilly USD 869.02B 146.97B Mar/2026
Enanta Pharmaceuticals USD 122M 98M Dec/2024
Esperion Therapeutics USD 885M 351M Dec/2025
Halozyme Therapeutics USD 7.66B 257M Mar/2026
Heron Therapeutics USD 238M 7M Dec/2025
Insmed USD 35.3B 1.82B Mar/2026
J&J USD 579.15B 78.91B Mar/2026
Lexicon Pharmaceuticals USD 418M 73M Dec/2025
Ligand Pharmaceuticals USD 3.98B 241M Mar/2026
Merck USD 297.1B 35.84B Mar/2026
Moderna USD 20.15B 8.53B Mar/2026
Pfizer USD 153.81B 12.24B Mar/2026
PTC Therapeutics USD 5.64B 460M Mar/2026
Sanofi EUR 100.27B 605.48M Mar/2026
Takeda JPY 9.01T 1.37T Mar/2026
Teva Pharmaceutical Industries USD 34.27B 2.14B Mar/2026
Ultragenyx Pharmaceutical USD 2.06B 159M Mar/2026
Vanda Pharmaceuticals USD 279M 6M Dec/2024
Veracyte USD 2.57B 758M Mar/2026